This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Europe's Problems Difficult but Can Be Solved

NXP Semiconductors (NXPI): "This market is too tough. I don't want you to buy any semiconductors right now. See you in September."

Clean Energy Fuels (CLNE): "This is completely speculative. You're betting on companies switching to natural gas. They haven't done it yet, so until then you're stuck."

VIVUS (VVUS): "I like it as a speculation. I think it's a good one."

Carter's (CRI): "Keep looking, don't touch. They have no growth. I don't want to touch any no-growth situations."

Executive Decision

In the "Executive Decision" segment, Cramer sat down with Clay Siegall, president and CEO of Seattle Genetics (SGEN), another cancer-fighting company presenting at the American Society of Clinical Oncology conference this week.

Siegall explained that Seattle Genetics' cancer drugs use target antibodies to dock with tumor cells and kill them while leaving surrounding, healthy cells untouched. He said the result is a less toxic, targeted therapy. Seattle Genetics is currently developing seven such treatments to attack both solid and liquid tumors.

Another part of Seattle Genetics' strategy is to utilize local community doctors, rather than large hospitals, to administer their treatments. He said the 30-minute infusions are easy to administer and patients much prefer to be seen by their regular doctors.

When asked about the potential of their treatments, Siegall said his company has 10 to 15 different trials in the pipeline and he's confident the treatments will be successful in treating different types of cancers as well.

With the frontline treatment for cancer having changed little since its introduction in 1977, Cramer said companies like Seattle Genetics are offering hope for newer, safer and more effective cancer treatments, which is why he remains bullish on the company.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer looked at the shares of Caterpillar (CAT), an industrial stock in the crosshairs of a potential global recession, to ask, "What's a fair valuation for this earth-moving equipment powerhouse?"

Cramer said Caterpillar shares have already fallen 30% from their high of $116. However, during the recession of 2008 and 2009, a time when earnings fell by 60%, shares of Caterpillar fell a whopping 75%. Could investors be in for a similar decline now to $36 a share?

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs